AzTrials
AzTrials

COVID-19NCT06070896

Advanced Modeling of the Evolution of the Epidemiological Outbreak of SARS-CoV-2 Pandemic

An observational study of COVID-19, run by Hospital Galdakao-Usansolo at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The various epidemics that health systems periodically suffers require having valid and detailed information on its evolution and predictions in the short, medium and long term in real time to allow the health system to organize itself in advance to be able to address the health and sanitary problem that this… Read more about this study

Who is it for?
Any age
Conditions the study is for
COVID-19
How many people
715,206 participants
Where
1 siteSpain
Study dates
1 Mar 2020to 31 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Information collected on daily incidence data aggregated by age and sex for: positive cases, hospital admissions and ICU admissions by SARS-CoV-2, hospital discharges and ICU discharges, recovered and mortality (in ICU, in hospital or in the community) of individuals with COVID19).

Who may be able to join

  • To be a positive SARS-CoV-2 infection laboratory-confirmed by a positive result on the reverse transcriptase-polymerase chain reaction assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a positive antigen test from March 1, 2020 to January 9, 2022
  • For hospital admissions:
  • Consider different episodes as a single admission when it comes to transfers from one center to another.
  • Exclusively admissions due to COVID-19.

Who cannot join

  • Patients admitted for other reasons who have developed the disease during their hospital stay.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Hospital Galdakao-Usansolo

    Galdakao, Bizkaia, 48960

Other trials in Spain

About this study

Official title: Advanced Modeling of the Evolution of an Epidemiological Outbreak to Predict Its Consequences in Terms of Use of Health Resources and Mortality

The various epidemics that health systems periodically suffers require having valid and detailed information on its evolution and predictions in the short, medium and long term in real time to allow the health system to organize itself in advance to be able to address the health and sanitary problem that this entails.The objectives of this proposal are: to study the usefulness of the health system's information and data storage system as a source for quickly and efficiently obtaining data necessary for modeling an epidemiological outbreak; its modeling in order to predict its evolution and the presentation of results to help in decision making. The investigatorswill rely on the experience obtained so far during the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, to define semi-automatic and flexible criteria for searching, extracting, cleaning and aggregating data. Predictions of incidence, number of hospital and ICU admissions, and number of deaths will be made at the Basque Country level.Within the analysis of temporal data, especially in the context of the pandemic, it is essential to have robust tools that allow accurate predictions. In this study, the investigators employed P-splines based on the negative binomial distribution to predict pandemic-related positive cases, hospital admissions, and ICU admissions.

Read the detailed description

Design. Retrospective observational study. The modeling will be based on the SARS-CoV-2 pandemic that started at the beginning of 2020.

Subjects of the study. Information will be collected on daily incidence data aggregated by age and sex for: tests performed, positive cases, hospital admissions and ICU admissions for SARS-CoV-2, hospital discharges and ICU discharges, recovered and mortality (in ICU, in hospital or in the community) of individuals with Coronavirus Disease of 2019 (COVID 19).

Criteria for inclusion. Of positive cases: Having a SARS-CoV-2 infection laboratory-confirmed by a positive result on the reverse transcriptase-polymerase chain reaction assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a positive antigen test from March 1, 2020 to January 9, 2022.

For hospital admissions: Hospital admissions since the start of the pandemic. Considering different episodes as a single admission when it comes to transfers from one center to another. Consider exclusively income due to the COVID19.

Exclusion criteria: Patients admitted for other reasons who have developed the disease during their hospital stay.

Variables. The data to be collected is aggregated data in the form of incidents. The population will be stratified into ten age groups (0 - 9, 10 - 19, ..., 70 - 79, 80 - 89, 90+) and by sex. Variables:

  • Individuals in the study population by age.
  • Number of new confirmed positive cases of COVID19 by age and day.
  • Number of new hospital admissions due to COVID19 by age and day. Number of ICU admissions due to COVID19
  • Number of total deaths from COVID19 by age and day.
  • Number of hospital discharges (live patients) of patients who have been hospitalized for COVID19 by age and day (excluding transfers).
  • Number of deaths in hospital due to COVID19 by age and day.
  • Number of deaths in the ICU due to COVID19 by age and day.

The outcome variables that will be obtained from the proposed modeling are:

  • Number of estimated positive COVID19 cases by age and day.
  • Number of estimated COVID19 hospital admissions by age and day.
  • Number of estimated total deaths due to COVID19 estimated by age and day.
  • Number of estimated ICU admissions due to COVID19 estimated by age and day.

Analysis of data. The investigators will use P-splines and Negative Binomial Distribution. P-splines, or penalized splines, are a powerful tool for modeling nonlinear relationships in temporal data. By combining them with the negative binomial distribution, a model is obtained that is especially suitable for counting data with over-dispersion, as is the case with pandemic data.

Procedure:

  • Data Collection: Daily data on positive cases, hospital admissions and ICU admissions will be obtained from the beginning of the pandemic until september 2022.
  • Modeling: A P-splines model based on the negative binomial distribution will be fitted to the data. This model will be designed to capture temporal trends and seasonal patterns, as well as to handle the over-dispersion present in the data.
  • Model with Random Effect for Day of the Week: Specifically for the prediction of hospital admissions, a random effect for the day of the week will be incorporated. This adjustment will be made because a systematic variability in income was identified depending on the day of the week. Incorporating this random effect significantly will improve the accuracy of the model for this variable.
  • Prediction: Predictions will be made for two time horizons: short term (1 and 2 days) and medium term (5 days). These predictions will allow us to anticipate the evolution of the pandemic and make informed decisions.

Validation of Predictions: To validate the accuracy and robustness of the predictions, a retrospective analysis will be carried out at different times (or waves) of the pandemic. Model predictions will be compared to actual observed data, and error metrics will be calculated to evaluate model performance.

Limitations. One of the limitations of the study is the possible loss of hospitalizations due to the disease considered and death (or recovery) in individuals whose temporal sequence of testing, admission and death (or recovery) has not followed the sequence used in searches carried out.

Ethical aspects. This study uses only anonymized information to meet its objectives. There is no data available to identify a patient.

The processing, communication and transfer of personal data of all participating persons complies with the provisions of the European Data Protection Regulation (EU2016/679) regarding the protection of natural persons with regard to processing. of personal data and the free circulation of these data and Organic Law 3/2018, of December 5, on the Protection of Personal Data and guarantee of digital rights. Virtually all of the data necessary for this study is aggregated data that in no case can be associated with individuals. All information will be treated absolutely confidentially.

Regarding obtaining informed consent from the patient, this research team proposes carrying out the study without asking the patient for informed consent. The reasons why this proposal is made are based on article 58 of Law 14/2007, of July 3, on Biomedical Research (""..exceptionally, coded or identified samples may be treated for the purposes of biomedical research without the consent of the source subject, when obtaining said consent is not possible or represents an unreasonable effort. In these cases, the favorable opinion of the corresponding Research Ethics Committee will be required. ")

Conditions
COVID-19
Keywords
COVID-19, Mathematical Model, Public Health
Medical subject headings
COVID-19

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. COVID19 positive cases

    Number of estimated positive COVID19 cases by age and day.

    Measured: Daily

  2. COVID19 hospital admissions

    Number of estimated COVID19 hospital admissions by age and day.

    Measured: Daily

  3. Deaths due to COVID19

    Number of total deaths due to COVID19 estimated by age and day.

    Measured: Daily

Secondary outcomes (1)
  1. ICU admissions

    •Number of ICU admissions due to COVID19 estimated by age and day.

    Measured: Daily

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Oct 2023
  2. Study start1 Mar 2020
  3. Primary completion30 Sep 2022
  4. Study completion31 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
715,206 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06070896
Sponsor's protocol ID
2020111078
Status last verified
Oct 2023
First submitted
5 Oct 2023
Last updated
28 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of COVID-19, run by Hospital Galdakao-Usansolo at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

COVID19 positive cases (time frame: Daily). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in